You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 31, 2024

SYMPAZAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Sympazan patents expire, and when can generic versions of Sympazan launch?

Sympazan is a drug marketed by Otter Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and sixty-eight patent family members in nineteen countries.

The generic ingredient in SYMPAZAN is clobazam. There are ten drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the clobazam profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Sympazan

A generic version of SYMPAZAN was approved as clobazam by AMNEAL on October 22nd, 2018.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for SYMPAZAN?
  • What are the global sales for SYMPAZAN?
  • What is Average Wholesale Price for SYMPAZAN?
Drug patent expirations by year for SYMPAZAN
Drug Prices for SYMPAZAN

See drug prices for SYMPAZAN

Pharmacology for SYMPAZAN

US Patents and Regulatory Information for SYMPAZAN

SYMPAZAN is protected by three US patents.

Patents protecting SYMPAZAN


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING SEIZURES

Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Otter Pharms SYMPAZAN clobazam FILM;ORAL 210833-001 Nov 1, 2018 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Otter Pharms SYMPAZAN clobazam FILM;ORAL 210833-003 Nov 1, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Otter Pharms SYMPAZAN clobazam FILM;ORAL 210833-002 Nov 1, 2018 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Otter Pharms SYMPAZAN clobazam FILM;ORAL 210833-003 Nov 1, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SYMPAZAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Otter Pharms SYMPAZAN clobazam FILM;ORAL 210833-001 Nov 1, 2018 ⤷  Sign Up ⤷  Sign Up
Otter Pharms SYMPAZAN clobazam FILM;ORAL 210833-003 Nov 1, 2018 ⤷  Sign Up ⤷  Sign Up
Otter Pharms SYMPAZAN clobazam FILM;ORAL 210833-002 Nov 1, 2018 ⤷  Sign Up ⤷  Sign Up
Otter Pharms SYMPAZAN clobazam FILM;ORAL 210833-001 Nov 1, 2018 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for SYMPAZAN

See the table below for patents covering SYMPAZAN around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 2120897 FILMS À BASE DE POLYMÈRES ET SYSTÈMES DE DÉLIVRANCE DE MÉDICAMENTS FABRIQUÉS À PARTIR DE CEUX-CI (POLYMER-BASED FILMS AND DRUG DELIVERY SYSTEMS MADE THEREFROM) ⤷  Sign Up
Australia 2002332118 ⤷  Sign Up
Japan 5165888 ⤷  Sign Up
Canada 2630261 COMPOSITIONS DE FILMS TOPIQUES POUR LA LIBERATION D'ACTIFS (TOPICAL FILM COMPOSITIONS FOR DELIVERY OF ACTIVES) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.